Raja Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raja Shaikh has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Ibrahim Alomari
Division of Vascular and Interventional Radiology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
5 shared publications - Horacio Padua
Boston Children's Hospital
5 shared publications - Mohammad Amarneh
Division of Vascular and Interventional Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
3 shared publications Anne Marie Cahill
Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publications- Darren B. Orbach
Neurointerventional Radiology, Boston Children's Hospital Harvard Medical School Boston MA USA
2 shared publications - Gulraiz Chaudry
Boston Children's Hospital
2 shared publications
Latest Publications
- 10 September 2026
- Published by Springer Nature in Pediatric Radiology
- p. 1-12
Image-guided ablation for pediatric malignant solid tumors: a review of modalities, evidence, and clinical applications
Image-guided percutaneous ablation has evolved into an increasingly utilized approach in selected pediatric oncologic indications. The evidence base remains thinner than clinical adoption would suggest. Most published series are small, retrospective, and limited to single institutional experiences. This review synthesizes evidence from 1995 through early 2025 on radiofrequency ablation (RFA), cryoablation, microwave ablation (MWA), irreversible electroporation (IRE), and electrochemotherapy across malignant solid tumors in patients aged 18 years or younger. Hepatoblastoma has shown the steepest rising incidence among ablation-relevant solid tumors with an annual percent change of +2.17%. Five-year survival for bone tumors and soft tissue sarcomas remains near 60%. For malignant solid tumors, the evidence remains limited to small retrospective series with heterogeneous populations and short follow-up, precluding conclusions about survival benefit. Surgical resection and systemic chemotherapy remain the primary treatment for all malignant solid tumors discussed; ablation is reserved for relapsed, refractory, or surgically limited scenarios. A coordinated multicenter registry with standardized survival endpoints remains the most urgent unmet need in the field. Graphical abstract
- 10 September 2026
- Published by Springer Nature in Pediatric Radiology
- p. 1-12
Image-guided ablation for pediatric malignant solid tumors: a review of modalities, evidence, and clinical applications
Image-guided percutaneous ablation has evolved into an increasingly utilized approach in selected pediatric oncologic indications. The evidence base remains thinner than clinical adoption would suggest. Most published series are small, retrospective, and limited to single institutional experiences. This review synthesizes evidence from 1995 through early 2025 on radiofrequency ablation (RFA), cryoablation, microwave ablation (MWA), irreversible electroporation (IRE), and electrochemotherapy across malignant solid tumors in patients aged 18 years or younger. Hepatoblastoma has shown the steepest rising incidence among ablation-relevant solid tumors with an annual percent change of +2.17%. Five-year survival for bone tumors and soft tissue sarcomas remains near 60%. For malignant solid tumors, the evidence remains limited to small retrospective series with heterogeneous populations and short follow-up, precluding conclusions about survival benefit. Surgical resection and systemic chemotherapy remain the primary treatment for all malignant solid tumors discussed; ablation is reserved for relapsed, refractory, or surgically limited scenarios. A coordinated multicenter registry with standardized survival endpoints remains the most urgent unmet need in the field. Graphical abstract
- 14 October 2025
- Published by Cassyni
Angioplasty for Renal Artery Stenosis in Children
## Introduction Renal artery stenosis (RAS) is a rare but important cause of hypertension in children patients. Percutaneous renal angioplasty (PTRA) offers a minimally invasive therapeutic option, but data on its efficacy in children remain limited, particularly if associated with mid-aortic stenosis. ## Materials and Methods This retrospective study included children with hypertension secondary to RAS who underwent PTRA at a tertiary care pediatric hospital. Data on patient characteristics, procedural details, and outcomes were collected. Clinical success was defined as improved blood pressure control or reduction in antihypertensive use. Technical success was categorized as complete (<25% residual stenosis) or partial (25–69% residual stenosis) resolution. Descriptive and subgroup analyses were performed. ## Results Fifteen patients (mean age 10.1 ± 4.2 years, 8 males) underwent 20 angioplasties. Five patients (33.3%) had mid-aortic syndrome (MAS). Most stenoses were right-sided (40%), with 26.7% bilateral. Hypertension was incidentally diagnosed in 73.3% of cases. Non-cutting balloons were used in 95% of procedures, and minor complications occurred in two cases (hematoma, intimal dissection). Clinical success was achieved in all procedures (100%), while technical success was complete in 60% and partial in 40%. Subgroup analysis showed no significant difference in outcomes between MAS-associated and isolated RAS. ## Discussion Percutaneous renal angioplasty is a safe and effective treatment for RAS in children, with high clinical success and acceptable technical outcomes.
- 14 October 2025
- Published by Cassyni
Angioplasty for Renal Artery Stenosis in Children
## Introduction Renal artery stenosis (RAS) is a rare but important cause of hypertension in children patients. Percutaneous renal angioplasty (PTRA) offers a minimally invasive therapeutic option, but data on its efficacy in children remain limited, particularly if associated with mid-aortic stenosis. ## Materials and Methods This retrospective study included children with hypertension secondary to RAS who underwent PTRA at a tertiary care pediatric hospital. Data on patient characteristics, procedural details, and outcomes were collected. Clinical success was defined as improved blood pressure control or reduction in antihypertensive use. Technical success was categorized as complete (<25% residual stenosis) or partial (25–69% residual stenosis) resolution. Descriptive and subgroup analyses were performed. ## Results Fifteen patients (mean age 10.1 ± 4.2 years, 8 males) underwent 20 angioplasties. Five patients (33.3%) had mid-aortic syndrome (MAS). Most stenoses were right-sided (40%), with 26.7% bilateral. Hypertension was incidentally diagnosed in 73.3% of cases. Non-cutting balloons were used in 95% of procedures, and minor complications occurred in two cases (hematoma, intimal dissection). Clinical success was achieved in all procedures (100%), while technical success was complete in 60% and partial in 40%. Subgroup analysis showed no significant difference in outcomes between MAS-associated and isolated RAS. ## Discussion Percutaneous renal angioplasty is a safe and effective treatment for RAS in children, with high clinical success and acceptable technical outcomes.
- 29 July 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (9) , 1305-1312
Outcomes of Percutaneous Cryoablation in Aneurysmal Bone Cysts: A Clinical and Imaging Analysis
To evaluate the clinical and imaging outcomes of percutaneous cryoablation as a minimally invasive alternative for ABCs in both treatment-naïve patients and those with prior treatment failures. In this retrospective analysis, 41 patients (mean age 13.6 years) with imaging- or biopsy-confirmed ABCs underwent 80 cryoablation procedures between December 2016 and November 2024. Procedures were performed under general anesthesia using real-time ultrasound, fluoroscopy, and CT guidance. A standard freeze-thaw-freeze protocol was applied, with adjustments for larger lesions and proximity to critical structures. Post-procedure monitoring included short-term observation followed by scheduled clinical evaluations and MRI scans at 3, 6, and 12 months. Clinical response was graded on a three-point scale (no, partial, and complete response), while imaging response was based on the percentage of lesion fibrosis. A complete clinical response was achieved in 78% of patients after a mean of 4.7 months, and a complete imaging response (> 75% fibrosis) in 78% after 16.4 months. Time to clinical response was similar between treatment-naïve (4.4 months) and previously treated patients (4.8 months). Mean time to > 75% fibrosis was 12.4 months in treatment-naïve and 17.5 months in previously treated patients. The mean number of procedures per patient was two, and cryoablation proved effective even in 83% of cases with previous treatment failure. Complications included a transient peroneal nerve injury and a wound infection, both managed successfully. Percutaneous cryoablation demonstrates high clinical and radiological success with a favorable safety profile, establishing it as a viable and effective treatment option for ABCs, particularly in recurrent or refractory cases.
- 29 July 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (9) , 1305-1312
Outcomes of Percutaneous Cryoablation in Aneurysmal Bone Cysts: A Clinical and Imaging Analysis
To evaluate the clinical and imaging outcomes of percutaneous cryoablation as a minimally invasive alternative for ABCs in both treatment-naïve patients and those with prior treatment failures. In this retrospective analysis, 41 patients (mean age 13.6 years) with imaging- or biopsy-confirmed ABCs underwent 80 cryoablation procedures between December 2016 and November 2024. Procedures were performed under general anesthesia using real-time ultrasound, fluoroscopy, and CT guidance. A standard freeze-thaw-freeze protocol was applied, with adjustments for larger lesions and proximity to critical structures. Post-procedure monitoring included short-term observation followed by scheduled clinical evaluations and MRI scans at 3, 6, and 12 months. Clinical response was graded on a three-point scale (no, partial, and complete response), while imaging response was based on the percentage of lesion fibrosis. A complete clinical response was achieved in 78% of patients after a mean of 4.7 months, and a complete imaging response (> 75% fibrosis) in 78% after 16.4 months. Time to clinical response was similar between treatment-naïve (4.4 months) and previously treated patients (4.8 months). Mean time to > 75% fibrosis was 12.4 months in treatment-naïve and 17.5 months in previously treated patients. The mean number of procedures per patient was two, and cryoablation proved effective even in 83% of cases with previous treatment failure. Complications included a transient peroneal nerve injury and a wound infection, both managed successfully. Percutaneous cryoablation demonstrates high clinical and radiological success with a favorable safety profile, establishing it as a viable and effective treatment option for ABCs, particularly in recurrent or refractory cases.
- 21 May 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (6) , 866-872
Cervical Intranodal Lymphangiogram in Pediatrics; Technique, Safety, and Clinical Applications
Purpose This paper introduces a novel technique, cervical lymphangiogram, involving intranodal lymphangiogram through cervical lymph nodes. We will discuss our preliminary experience regarding the technique, safety, and applications, offering a promising approach to addressing central conducting duct opacification challenges. Material and methods This retrospective study was IRB exempt. All patients failed conservative management for treatment of chylous effusion. Patients who underwent cervical lymphangiogram as either diagnostic or therapeutic process were included. All patients were imaged with magnetic resonance lymphangiogram (MRL) followed by fluoroscopic inguinal intranodal lymphangiogram with failure to opacify thoracic duct or source of chylous effusion. Both, intranodal lymphangiograms and MRL were performed using water-soluble contrast due to the risk of paradoxical emboli given either suspected or confirmed right-to-left shunts. Results Cervical lymphangiogram was performed on 7 patients with ages ranging from 40 days to 8 years. Etiology included unilateral or bilateral chylous pleural effusions. Technical success (defined as opacification of thoracic duct depicting its anatomy, revealing the underlying disorder, either a leak or congenital anomaly) rate was 100%. Clinical success (defined by resolution of symptoms) rate was 100% in patients that showed evidence of leak and underwent glue embolization (6 out of 7 patients). No technique-related complications incurred in any patients. The mean follow-up duration to exclude recurrence and watch for complications was 150 days. Conclusion Cervical lymphangiogram is a promising and safe technique to evaluate central conducting ducts where inguinal lymphangiograms (intranodal or MRL) have failed to demonstrate the same. Graphical Abstract
- 21 May 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (6) , 866-872
Cervical Intranodal Lymphangiogram in Pediatrics; Technique, Safety, and Clinical Applications
Purpose This paper introduces a novel technique, cervical lymphangiogram, involving intranodal lymphangiogram through cervical lymph nodes. We will discuss our preliminary experience regarding the technique, safety, and applications, offering a promising approach to addressing central conducting duct opacification challenges. Material and methods This retrospective study was IRB exempt. All patients failed conservative management for treatment of chylous effusion. Patients who underwent cervical lymphangiogram as either diagnostic or therapeutic process were included. All patients were imaged with magnetic resonance lymphangiogram (MRL) followed by fluoroscopic inguinal intranodal lymphangiogram with failure to opacify thoracic duct or source of chylous effusion. Both, intranodal lymphangiograms and MRL were performed using water-soluble contrast due to the risk of paradoxical emboli given either suspected or confirmed right-to-left shunts. Results Cervical lymphangiogram was performed on 7 patients with ages ranging from 40 days to 8 years. Etiology included unilateral or bilateral chylous pleural effusions. Technical success (defined as opacification of thoracic duct depicting its anatomy, revealing the underlying disorder, either a leak or congenital anomaly) rate was 100%. Clinical success (defined by resolution of symptoms) rate was 100% in patients that showed evidence of leak and underwent glue embolization (6 out of 7 patients). No technique-related complications incurred in any patients. The mean follow-up duration to exclude recurrence and watch for complications was 150 days. Conclusion Cervical lymphangiogram is a promising and safe technique to evaluate central conducting ducts where inguinal lymphangiograms (intranodal or MRL) have failed to demonstrate the same. Graphical Abstract
- 15 March 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (6) , 1112-1117
Qualitative evaluation of magnetic resonance imaging features in aneurysmal bone cysts after percutaneous cryoablation
Background Aneurysmal bone cysts (ABCs) are benign vascular lesions commonly affecting the pediatric population. Objective To assess magnetic resonance imaging (MRI) features of ABCs after percutaneous cryoablation. Materials and methods A retrospective review of the hospital’s electronic medical record database was conducted to identify patients who underwent percutaneous image-guided cryoablation for aneurysmal bone cysts between March 2014 and April 2024. Patients were excluded if they lacked pre- or post-treatment MRI, underwent surgical curettage and bone grafting between cryoablation treatments, or received adjunctive therapies such as sclerotherapy or bone grafting. Demographic data and pre- and post-cryoablation MRI characteristics of the lesions were collected and analyzed. Results We retrospectively analyzed 20 patients (mean age = 14.6 years). The average ABC volume decreased from 83 cm3 pre-treatment to 32.7 cm3 post-treatment. In the final post-treatment MRI, there was a 50% decrease in the cystic component in 90% (n = 18) of patients, improved cortical integrity in 75% (n = 9), resolution of peri-lesional edema and mass effect in all (n = 20), and development of organized fibrosis in 50% (n = 10) of the patients. The average time was 8.3 months for a 50% reduction in cystic component, 7.3 months for improvement in cortical integrity, 6.4 months for improvement in mass effect, 15 months for complete resolution of peri-lesional enhancement, and 16.1 months for the development of organized fibrosis. Conclusion These findings suggest MRI is a valuable tool for monitoring ABC response to cryotherapy, guiding future treatment protocols. Graphical Abstract
- 15 March 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (6) , 1112-1117
Qualitative evaluation of magnetic resonance imaging features in aneurysmal bone cysts after percutaneous cryoablation
Background Aneurysmal bone cysts (ABCs) are benign vascular lesions commonly affecting the pediatric population. Objective To assess magnetic resonance imaging (MRI) features of ABCs after percutaneous cryoablation. Materials and methods A retrospective review of the hospital’s electronic medical record database was conducted to identify patients who underwent percutaneous image-guided cryoablation for aneurysmal bone cysts between March 2014 and April 2024. Patients were excluded if they lacked pre- or post-treatment MRI, underwent surgical curettage and bone grafting between cryoablation treatments, or received adjunctive therapies such as sclerotherapy or bone grafting. Demographic data and pre- and post-cryoablation MRI characteristics of the lesions were collected and analyzed. Results We retrospectively analyzed 20 patients (mean age = 14.6 years). The average ABC volume decreased from 83 cm3 pre-treatment to 32.7 cm3 post-treatment. In the final post-treatment MRI, there was a 50% decrease in the cystic component in 90% (n = 18) of patients, improved cortical integrity in 75% (n = 9), resolution of peri-lesional edema and mass effect in all (n = 20), and development of organized fibrosis in 50% (n = 10) of the patients. The average time was 8.3 months for a 50% reduction in cystic component, 7.3 months for improvement in cortical integrity, 6.4 months for improvement in mass effect, 15 months for complete resolution of peri-lesional enhancement, and 16.1 months for the development of organized fibrosis. Conclusion These findings suggest MRI is a valuable tool for monitoring ABC response to cryotherapy, guiding future treatment protocols. Graphical Abstract
- 5 September 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (12) , 1776-1783
Cryoablation in Extra-Abdominal Desmoid Tumors: A 10-Year Experience in Pediatric and Young Adult Patients
Purpose To determine the efficacy and safety of cryoablation in pediatric and young adult patients with desmoid tumors (DTs) retrospectively over a 10-year period. Materials and Methods Twenty-one patients (age 2–22 years; median 14 years), with 21 desmoid tumors, underwent a total of 34 percutaneous cryoablation procedures between August 2013 and August 2023. All patients, excluding two, had surgical resection, chemotherapy, or a combination of these therapies with failed or suboptimal response. Clinical and imaging outcomes were analyzed for technical success, change in tumor volume, and recurrence of tumor, symptom improvement or recurrence, and procedure-related complications. Results All procedures were technically successful. The median follow-up duration was 9 months (range, 3–32 months); total symptomatic improvement was achieved in 90% (19/21) patients, noticeable pain relief was seen in 100% (18/18) and 90% (9/10) patients had improved range of motion (ROM), discomfort resolved in 66.7% (2/3) patients. Of the treated tumors, 43% (9/21) showed greater than 75% tumor volume reduction of which 44% (4/9) had no evidence of viable residual tumor at follow-up, and 33% (7/21) had 50–75% volume reduction and 14% (3/21) had greater than 40–50% tumor volume reduction. According to modified response evaluation criteria in solid tumors (mRECIST), 71%( 15/21) had partial response (PR), 19% (4/21) had complete response (CR), and 10% (2/21) had stable disease. Four (12%) treatments were associated with minor complications, which self-resolved. Conclusion In this, predominantly pediatric patient cohort, cryoablation was effective and safe for the local control of extra-abdominal desmoid tumors in short-term follow-up. Graphical Abstract
- 5 September 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (12) , 1776-1783
Cryoablation in Extra-Abdominal Desmoid Tumors: A 10-Year Experience in Pediatric and Young Adult Patients
Purpose To determine the efficacy and safety of cryoablation in pediatric and young adult patients with desmoid tumors (DTs) retrospectively over a 10-year period. Materials and Methods Twenty-one patients (age 2–22 years; median 14 years), with 21 desmoid tumors, underwent a total of 34 percutaneous cryoablation procedures between August 2013 and August 2023. All patients, excluding two, had surgical resection, chemotherapy, or a combination of these therapies with failed or suboptimal response. Clinical and imaging outcomes were analyzed for technical success, change in tumor volume, and recurrence of tumor, symptom improvement or recurrence, and procedure-related complications. Results All procedures were technically successful. The median follow-up duration was 9 months (range, 3–32 months); total symptomatic improvement was achieved in 90% (19/21) patients, noticeable pain relief was seen in 100% (18/18) and 90% (9/10) patients had improved range of motion (ROM), discomfort resolved in 66.7% (2/3) patients. Of the treated tumors, 43% (9/21) showed greater than 75% tumor volume reduction of which 44% (4/9) had no evidence of viable residual tumor at follow-up, and 33% (7/21) had 50–75% volume reduction and 14% (3/21) had greater than 40–50% tumor volume reduction. According to modified response evaluation criteria in solid tumors (mRECIST), 71%( 15/21) had partial response (PR), 19% (4/21) had complete response (CR), and 10% (2/21) had stable disease. Four (12%) treatments were associated with minor complications, which self-resolved. Conclusion In this, predominantly pediatric patient cohort, cryoablation was effective and safe for the local control of extra-abdominal desmoid tumors in short-term follow-up. Graphical Abstract
- 28 June 2024
- Published by Elsevier in Techniques in Vascular and Interventional Radiology
- Vol. 27 (2) , 100961
Fibroadipose Vascular Anomaly: Diagnosis and Treatment
- 28 June 2024
- Published by Elsevier in Techniques in Vascular and Interventional Radiology
- Vol. 27 (2) , 100961
Fibroadipose Vascular Anomaly: Diagnosis and Treatment
- 14 March 2024
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 08 (02) , 130-136
Interventional Radiology Management of Pediatric Liver Tumors
Pediatric liver tumors are not only rare, they are also different from the adult liver tumors. Hepatoblastomas and hepatocellular carcinomas (HCCs) are the most common primary malignant tumors seen in children. Fibrolamellar HCC, sarcomas, cholangiocarcinoma, germ cell tumor, and rhabdoid tumor and metastatic tumors comprise the remainder of liver malignancies. Hepatic infantile hemangiomas, mesenchymal hamartoma, regenerative nodules, adenomas, and focal nodular hyperplasia are the common benign liver tumors of childhood. The Pediatric Hepatic International Tumour Trial (PHITT) is an international trial with the goal of evaluating new and existing treatments for pediatric liver tumors. Chemotherapy, surgery, and liver transplantation are well-established in the management of pediatric liver tumors. In the background of increasing incidence of pediatric tumors, and availability of newer, less invasive modalities to treat tumors, it is vital to understand the role of interventional radiology in the management of pediatric liver tumors.
- 14 March 2024
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 08 (02) , 130-136
Interventional Radiology Management of Pediatric Liver Tumors
Pediatric liver tumors are not only rare, they are also different from the adult liver tumors. Hepatoblastomas and hepatocellular carcinomas (HCCs) are the most common primary malignant tumors seen in children. Fibrolamellar HCC, sarcomas, cholangiocarcinoma, germ cell tumor, and rhabdoid tumor and metastatic tumors comprise the remainder of liver malignancies. Hepatic infantile hemangiomas, mesenchymal hamartoma, regenerative nodules, adenomas, and focal nodular hyperplasia are the common benign liver tumors of childhood. The Pediatric Hepatic International Tumour Trial (PHITT) is an international trial with the goal of evaluating new and existing treatments for pediatric liver tumors. Chemotherapy, surgery, and liver transplantation are well-established in the management of pediatric liver tumors. In the background of increasing incidence of pediatric tumors, and availability of newer, less invasive modalities to treat tumors, it is vital to understand the role of interventional radiology in the management of pediatric liver tumors.
- 14 August 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (9) , 1249-1256
Cryoablation for Bone and Soft Tissue Lesions in Pediatric Patients: Complications and Preventive Measures
Purpose To evaluate complications associated with cryoablation in a pediatric population and review preventive measures to mitigate these complications. Material and Methods Retrospective study including all the image guided cryoablations performed on pediatric population. Immediate and delayed complications were analyzed, and we identified the different protective measures used and the clinical outcomes from follow-up. Point estimates for the percentage of complications were calculated by maximum likelihood, and 95% confidence intervals for the true percentages were calculated using the Clopper-Pearson exact method. Results Eighty-seven ablations were performed on 68 patients (age range of 2–18 years, mean 12.4 years) for non-neoplastic (70%) and neoplastic (30%) lesions. The percentage of ablations resulting in complications was 18% (95% confidence interval (CI) 11% to 28%). Of these, 5% (95% CI 1% to 11%) were grade 3 complications, and 14% (95% CI 7% to 23%) were grade 2 complications. Thermal protection was performed in 27.6% of ablations (n = 24). The mean clinical follow-up duration was 348 days. Conclusion Cryoablation in pediatric patients is relatively safe, with a major complication rate per ablation of 5%. Thermal protective measures can be considered to mitigate these complications.
- 14 August 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (9) , 1249-1256
Cryoablation for Bone and Soft Tissue Lesions in Pediatric Patients: Complications and Preventive Measures
Purpose To evaluate complications associated with cryoablation in a pediatric population and review preventive measures to mitigate these complications. Material and Methods Retrospective study including all the image guided cryoablations performed on pediatric population. Immediate and delayed complications were analyzed, and we identified the different protective measures used and the clinical outcomes from follow-up. Point estimates for the percentage of complications were calculated by maximum likelihood, and 95% confidence intervals for the true percentages were calculated using the Clopper-Pearson exact method. Results Eighty-seven ablations were performed on 68 patients (age range of 2–18 years, mean 12.4 years) for non-neoplastic (70%) and neoplastic (30%) lesions. The percentage of ablations resulting in complications was 18% (95% confidence interval (CI) 11% to 28%). Of these, 5% (95% CI 1% to 11%) were grade 3 complications, and 14% (95% CI 7% to 23%) were grade 2 complications. Thermal protection was performed in 27.6% of ablations (n = 24). The mean clinical follow-up duration was 348 days. Conclusion Cryoablation in pediatric patients is relatively safe, with a major complication rate per ablation of 5%. Thermal protective measures can be considered to mitigate these complications.